The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
To investigate the safety and efficacy of deferoxamine (DFO) combined with conventional
transarterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma
(HCC).